Covering the operations of the oil and gas industry
General Interest
Refining & Processing
Drilling & Production
Exploration & Development
Pipelines & Transportation
Sections
General Interest
Refining & Processing
Drilling & Production
Exploration & Development
Pipelines & Transportation
LNG
Energy Transition
Industry Statistics
Members Only
Special
Webcasts
White Papers
Podcast
Magazine
Surveys
Research
Events
Submit an Article
Iran war
Contact
About Us
Subscribe
Newsletters
Advertise
Contact Us
Privacy Policy
Terms & Conditions
Affiliated Brands
OFFSHORE
ENERGYTECH
MICROGRID KNOWLEDGE
OGJ RESEARCH
Follow us on
http://www.facebook.com/ogjonline
https://www.linkedin.com/company/oil-&-gas-journal
http://twitter.com/ogjonline
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Nasdaq Composite
SPX
Gold
Crude+Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Aura Biosciences, Inc. - Common Stock
(NQ:
AURA
)
7.546
+0.156 (+2.11%)
Streaming Delayed Price
Updated: 1:31 PM EDT, May 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aura Biosciences, Inc. - Common Stock
< Previous
1
2
Next >
3 Small-Cap Stocks Ready to Deliver Significant Growth
October 10, 2024
Small-cap firms will have an easier time borrowing money for growth in a lower-interest-rate environment; these are a few companies poised for a breakout.
Via
MarketBeat
Topics
Economy
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
March 27, 2024
From
Aura Biosciences, Inc.
Via
Business Wire
Aura Biosciences to Participate in Upcoming Investor Conferences
February 26, 2024
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma
December 07, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
November 09, 2023
From
Aura Biosciences, Inc.
Via
Business Wire
Aura Biosciences to Participate in Upcoming Investor Conferences
November 08, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences Announces Pricing of Public Offering of Common Stock
November 06, 2023
From
Aura Biosciences, Inc.
Via
Business Wire
Aura Biosciences Announces Proposed Public Offering of Common Stock
November 06, 2023
From
Aura Biosciences, Inc.
Via
Business Wire
Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma
November 06, 2023
From
Aura Biosciences, Inc.
Via
Business Wire
Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023
October 31, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments
October 02, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
August 09, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences to Participate in Upcoming Investor Conferences
May 24, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences to Participate in the JMP Securities Life Sciences Conference
May 12, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
May 11, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights
March 15, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration
February 16, 2023
From
Aura Biosciences, Inc.
Via
Business Wire
Aura Biosciences to Participate in Upcoming Investor Conferences
February 09, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences Announces Pricing of Public Offering of Common Stock
November 30, 2022
From
Aura Biosciences, Inc.
Via
Business Wire
Aura Biosciences Announces Proposed Public Offering of Common Stock
November 30, 2022
From
Aura Biosciences, Inc.
Via
Business Wire
Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
November 10, 2022
From
Aura Biosciences
Via
Business Wire
Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma
November 10, 2022
From
Aura Biosciences, Inc.
Via
Business Wire
Aura Biosciences to Participate in Upcoming Investor Conferences
November 03, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022
October 03, 2022
From
Aura Biosciences, Inc.
Via
Business Wire
Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
September 28, 2022
From
Aura Biosciences, Inc.
Via
Business Wire
Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022
September 27, 2022
From
Aura Biosciences, Inc.
Via
Business Wire
Aura Biosciences to Present Phase 2 Safety Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) in Patients with Choroidal Melanoma at the ESMO 2022 Congress
September 07, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress
September 01, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
August 11, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences to Participate at the 2022 BTIG Biotechnology Conference
August 02, 2022
From
Aura Biosciences, Inc.
Via
Business Wire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
